Clinical Study Data Request Registered Users, Please Login

Find by:

Study ID:
Medicine:
Phase:

Immunogenicity and Safety of Sanofi Pasteur’s AVAXIM 80U Pediatric Vaccine Administered in Healthy Adolescents, Children and Toddlers in People’s Republic of China Followed by a Booster Dose 6 Months after the Initial Dose Versus HAVRIX 720 Vaccine
Inactivated Hepatitis A Vaccine
HAF78
NCT00483470
Eudract2015-005191-18
Active immunisation against hepatitis A infection
Phase 3
 
Datasets and document are available as per Sanofi Policy and criteria
December 2017

Powered by ideaPoint, Inc.